Verona’s £44.7m gross raise removes funding uncertainty, allowing the company to focus on the clinical progress of its respiratory asset RPL554, a dual PDE3/PDE4 inhibitor. RPL554 is in development in chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Verona now has the resources to run a Phase II programme, taking it through multiple potential value infection points in the next 18-24 months, and has committed to raising further funds via a future NASDAQ listing.
